AMT-130 Shows 75% Slowing in Huntington’s Progression: Strong Clinical Evidence
uniQure’s latest data reveal a pivotal moment for AMT-130, its lead gene therapy program targeting Huntington’s disease. In topline results from the Phase I/II study, high-dose AMT-130 demonstrated a statistically significant 75% slowing in disease progression at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale (cUHDRS; p=0.003). The key secondary endpoint, Total Functional Capacity, also met significance with a 60% slowing compared to matched external controls (p=0.033). Biomarker results backed these outcomes, with an average 8.2% reduction in neurofilament light protein at the same interval.
Safety was a notable strength: no new drug-related serious adverse events have occurred since December 2022. Adverse events were mainly procedural and manageable. The trial's three-year horizon strengthens confidence in the therapy's impact and durability, marking a clinical milestone in the pursuit of Huntington’s treatments.
Regulatory Outlook: FDA Signals Shift, Clouding Approval Timeline
Despite the impressive clinical results, regulatory uncertainty has come to the forefront. Following a recent pre-BLA (Biologics License Application) meeting, uniQure reported that the FDA now appears hesitant to accept AMT-130's Phase I/II data using an external control group as the main evidence for a BLA submission—departing from earlier feedback. With final minutes pending, uniQure is urgently engaging with regulators to clarify the path to approval. The submission timing is now uncertain, and investors should be aware that FDA expectations may require additional or different data for accelerated approval.
Robust Cash Position Following $323.7M Raise Supports R&D Momentum
Financially, uniQure is on solid ground. The company ended Q3 2025 with $694.2 million in cash, cash equivalents, and current investment securities, bolstered by a $323.7 million follow-on offering. Management projects this capital will fund operations into 2029. This extended runway positions uniQure to navigate both regulatory requirements and the ongoing development of its pipeline, including AMT-130, AMT-260 (epilepsy), and AMT-191 (Fabry disease).
| Financial Highlights (USD, thousands) | Q3 2025 | Q3 2024 |
|---|---|---|
| Total revenues | $3,701 | $2,287 |
| R&D expenses | ($34,366) | ($30,595) |
| SG&A expenses | ($19,438) | ($11,575) |
| Net loss | ($80,529) | ($44,378) |
| Cash, cash equivalents, and investments (period end) | $694,245 | $367,521 |
Pipeline Progress Beyond Huntington’s: AMT-260 and AMT-191 Show Early Promise
In addition to AMT-130, uniQure is advancing AMT-260 for mesial temporal lobe epilepsy and AMT-191 for Fabry disease. Early clinical data for AMT-191 show patients maintaining enzyme levels 27 to 208 times above the normal mean, allowing withdrawal from standard therapy with no major safety concerns so far. Further clinical updates on these candidates are expected in the first half of 2026.
The company did, however, pause the AMT-162 ALS trial following a dose-limiting toxicity, reflecting the risks that remain in the gene therapy development space.
Investor Takeaway: Strong Clinical Data, Clear Financial Strength, Regulatory Path Under Review
uniQure’s third-quarter results spotlight a potentially transformative therapy for Huntington’s disease and a well-capitalized operation capable of driving multiple programs forward. However, regulatory uncertainty means the timeline for bringing AMT-130 to patients remains open. With robust trial data in hand, the company’s next moves with the FDA could determine whether it sustains its current momentum or must adjust to evolving requirements. Investors and industry watchers should track FDA feedback over the coming months—progress on AMT-130 will shape the company’s future, while ongoing trials for epilepsy and Fabry disease may add further upside if data trends continue positively.
uniQure will provide further commentary on its investor webcast and conference call at 8:30 a.m. ET today, accessible via its website. Upcoming investor conferences on November 12 and 13 may also shed more light on management’s outlook.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI